HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Testicular seminoma in Denmark 1976-1980. Results of treatment.

Abstract
Over a five-year period the DATECA Study included 554 consecutive patients with seminoma, representing practically all cases in the country. The stage distribution was: stage I 424 patients, stage II 110 patients, and stage III 17 patients. Typical seminoma was registered in 515 patients, anaplastic seminoma in 26 patients, and spermatocytic seminoma in 13 patients. The treatment was post-operative irradiation except in a few very advanced cases who received chemotherapy. Three-year corrected survival was: stage I 99 per cent, stage II 89 per cent, and stage III 65 per cent. Anaplastic seminoma showed a significantly higher rate of metastatic spread than typical seminoma and the prognosis was worse. Treatment-related complications were few, but adjuvant bleomycin combined with irradiation of advanced seminoma resulted in 2 deaths from pneumonitis.
AuthorsH P Schultz, H von der Maase, M Rørth, M Pedersen, E Sandberg Nielsen, S Walbom-Jørgensen
JournalActa radiologica. Oncology (Acta Radiol Oncol) Vol. 23 Issue 4 Pg. 263-70 ( 1984) ISSN: 0349-652X [Print] Sweden
PMID6208748 (Publication Type: Journal Article)
Chemical References
  • Bleomycin
  • Vinblastine
  • Cisplatin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Bleomycin (administration & dosage, adverse effects)
  • Castration
  • Cisplatin (administration & dosage, adverse effects)
  • Combined Modality Therapy
  • Diarrhea (etiology)
  • Dysgerminoma (drug therapy, mortality, pathology, radiotherapy)
  • Follow-Up Studies
  • Humans
  • Male
  • Nausea (etiology)
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Pneumonia (etiology)
  • Radiation Injuries
  • Testicular Neoplasms (drug therapy, mortality, pathology, radiotherapy)
  • Vinblastine (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: